Key points are not available for this paper at this time.
Abstract Current evidences indicate that efforts to develop novel antipsychotic agents with multipronged mechanisms of action have been limited. The study evaluated the behavioural activities of ethanolic extract of Schumanniophyton magnificum leaves in mice. It investigated the neuro-behavioral and antioxidant properties of the ethanolic extract of Schumanniophyton magnificum leaves administered through the oral route of mice at different doses for 14 days. The behavioral assessment was demonstrated using the Open Field Test for assessing the ketamine-induced hyperlocomotion, Y-Maze test was used for assessing the behavior, learning and memory (cognition) and novel object recognition test to evaluate the willingness of the mice to explore new environment or object in animal models of the central nervous disorders. This research shows that after 14 days of administration, the animals were sacrificed and antioxidant bioassay was carried out on the brain. Schumanniophyton magnificum treatment (100, 200, and 400 mg/kg) significantly (P Schumanniophyton magnificum treatment (100 and 400 mg/kg) significantly enhanced spatial memory formation preventing cognitive deficits by ketamine. Additionally, Schumanniophyton magnificum treatment (100, 200, and 400 mg/kg) significantly increased the SOD & CAT activities, as well as decreased MDA levels, this is suggesting that the antipsychotic-like action of Schumanniophyton magnificum maybe through inhibition of oxidative crises induced by ketamine. Therefore this plant might be one of the plants to watch out for the treatment of psychosis.
Olusola et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: